• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Medicine >The serum levels of MMP-9 MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction
【2h】

The serum levels of MMP-9 MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction

机译：低剂量尿激酶腹膜透析患者的血清MMP-9MMP-2和vWF水平降低尿毒症并发脑梗死

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To investigate the effect of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction. 112 cases of uremia complicated with cerebral infarction were randomly divided into the peritoneal dialysate with urokinase treatment group (66 cases) and the conventional treatment group (46 cases). At the same time, 50 cases of healthy people who were more than 45 years old were enrolled in the control group. The basic treatment in both treatment groups was the same. In urokinase therapy group based on the conventional treatment, urokinase was added into peritoneal dialysis fluid, and changes of serum MMP-9, MMP-2 and vWF were observed by drawing blood at different time points within 8 weeks. The changes of serum MMP-2, MMP-9 and vWF were detected by enzyme-linked immunosorbent assay. At the time of the onset of uremia complicated with cerebral infarction patients the serum MMP-9, MMP-2, vWF were significantly higher (P<0.05, P<0.05, P<0.01). Conventional antiplatelet therapy in brain protection only reduce MMP-9 to the normal range (P>0.05) within 8 weeks. But the MMP-2 and vWF cannot be reduced to the normal range (P<0.01, P<0.01). Low doses of urokinase can reduce MMP-9 (7 d) and MMP-2 (14 d) to the normal range (P>0.05, P>0.05) at the early stage and decrease the vWF to a normal range within 8 weeks (P>0.05). At the time of the onset of uremia complicated with cerebral infarction patients the serum MMP-9, MMP-2 and vWF increased significantly. Low doses of urokinase dialysis can reduce serum MMP-9, MMP-2, and vWF in acute uremia complicated with cerebral infarction without recurrence of cerebral infarction and cerebral hemorrhagic transformation, indicating that low dose of urokinase peritoneal dialysis may have a certain effect on the early treatment of this disease.
机译：为了研究MMP-9，MMP-2和vWF在低剂量尿激酶腹膜透析患者中​​的作用，可降低尿毒症并发脑梗塞。将112例尿毒症并发脑梗死患者随机分为尿激酶腹膜透析液治疗组（66例）和常规治疗组（46例）。同时，将50例45岁以上的健康人纳入对照组。两个治疗组的基本治疗方法相同。在常规治疗基础上的尿激酶治疗组，在腹膜透析液中加入尿激酶，通过在8周内的不同时间抽血观察血清MMP-9，MMP-2和vWF的变化。酶联免疫吸附法检测血清MMP-2，MMP-9和vWF的变化。在尿毒症并发脑梗死患者发病时，血清MMP-9，MMP-2，vWF明显升高（P <0.05，P <0.05，P <0.01）。脑保护中的常规抗血小板治疗只能在8周内将MMP-9降低至正常范围（P> 0.05）。但是MMP-2和vWF不能降低到正常范围（P <0.01，P <0.01）。低剂量尿激酶可使早期MMP-9（7 d）和MMP-2（14 d）降至正常范围（P> 0.05，P> 0.05），并在8周内将vWF降至正常范围（ P> 0.05）。在尿毒症并发脑梗死患者发作时，血清MMP-9，MMP-2和vWF显着增加。低剂量尿激酶透析可降低急性尿毒症并发脑梗死时的血清MMP-9，MMP-2和vWF，而不会复发脑梗塞和脑出血，这说明低剂量尿激酶腹膜透析可能对尿毒症患者有一定的作用。对此病的早期治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号